Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient – a case report

• Main Authors: Ramaswamy R, Joshi N, Khan MA, Siddhara S
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-07-01
• Series: OncoTargets and Therapy
• Subjects: NDLS; PABC; DoceAqualip; pregnancy; breast cancer; metastatic
• Online Access: https://www.dovepress.com/nanosomal-docetaxel-lipid-suspension-based-chemotherapy-in-a-pregnant--peer-reviewed-article-OTT

Rajkumar Ramaswamy,1 Nisarg Joshi,2 Mujtaba A Khan,2 Seerin Siddhara11Department of Medical Oncology, Velammal Medical College and Research Institute, Madurai, Tamil Nadu 625009, India; 2Department of Medical Affairs & Clinical Development, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380054, IndiaAbstract: The current report presents a case of a pregnant woman with breast cancer metastasized to liver and lungs. The standard of care for breast cancer in pregnancy is anthracycline/taxane-based chemotherapy regimens. Docetaxel has shown a favorable toxicity profile during the second and third trimesters of pregnancy. A novel nanosomal docetaxel lipid suspension (NDLS) (DoceAqualip), with a proven efficacy and tolerability profile, has been approved in India for the treatment of advanced solid tumors since 2013. We present here a case of a pregnant woman with metastatic breast cancer managed with NDLS based TAC regimen showing a partial response after six cycles. The patient delivered a healthy male child with normal Apgar score and weight at the 32nd week of gestation.Keywords: NDLS, PABC, DoceAqualip, pregnancy, breast cancer, metastatic